The units on an insulin syringe are NOT the same as "units of tirzepatide." This trips people up constantly
The extended half-life of approximately 5 days allows for convenient weekly dosing, improving adherence compared to daily injectable therapies
Obesity is increasingly viewed as a chronic disease, and only bariatric surgery, endoscopic sleeve gastroplasty, and GLP-1 receptor agonist agents have demonstrated efficacy for sustained, clinically important weight loss
Do not assume that tirzepatide is interfering with your recovery
however, the majority have included placebo-controlled trials or studies incorporating combination therapies
As of 2026, 503A compounding pharmacies cannot legally produce compounded tirzepatide except in narrow, medically documented cases